Fig. 2.
Combined treatment with 1,25(OH)2D3 and AZA significantly reduces primary AML blasts ex vivo. A Human AML patient BM cells were cultured with 1,25(OH)2D3 and AZA as single agents and in combination. 48 h later, the cells were harvested and analyzed by FACS for expressions of CD117 and CD13 among viable cells. Representative FACS plots show viable blasts (CD13+CD117+ viability dye–) under the indicated conditions. B Percentages of CD13+ CD117+ AML blast cells under indicated conditions. C Percentages of CD34+ HSCs under indicated conditions (N = 3). D Therapeutic effect of 1,25(OH)2D3, AZA and their combination on AML patient samples after 48 h. Where applicable, data are means ± SEM from each group and were analyzed by Student t-test. *p < 0.05.